A mechanism for hereditary angioedema with normal C1 inhibitor

an inhibitory regulatory role for the factor XII heavy chain

Ivan Ivanov, Anton Matafonov, Mao Fu Sun, Bassem M. Mohammed, Qiufang Cheng, S. Kent Dickeson, Suman Kundu, Ingrid M. Verhamme, Andras Gruber, Keith McCrae, David Gailani

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The plasma proteins factor XII (FXII) and prekallikrein (PK) undergo reciprocal activation to the proteases FXIIa and kallikrein by a process that is enhanced by surfaces (contact activation) and regulated by the serpin C1 inhibitor. Kallikrein cleaves high-molecular-weight kininogen (HK), releasing the vasoactive peptide bradykinin. Patients with hereditary angioedema (HAE) experience episodes of soft tissue swelling as a consequence of unregulated kallikrein activity or increased prekallikrein activation. Although most HAE cases are caused by reduced plasma C1-inhibitor activity, HAE has been linked to lysine/arginine substitutions for Thr309 in FXII (FXII-Lys/Arg309). Here, we show that FXII-Lys/Arg309 is susceptible to cleavage after residue 309 by coagulation proteases (thrombin and FXIa), resulting in generation of a truncated form of FXII (δFXII). The catalytic efficiency of δFXII activation by kallikrein is 15-fold greater than for full-length FXII. The enhanced rate of reciprocal activation of PK and δFXII in human plasma and in mice appears to overwhelm the normal inhibitory function of C1 inhibitor, leading to increased HK cleavage. In mice given human FXII-Lys/Arg309, induction of thrombin generation by infusion of tissue factor results in enhanced HK cleavage as a consequence of δFXII formation. The effects of δFXII in vitro and in vivo are reproduced when wild-type FXII is bound by an antibody to the FXII heavy chain (HC; 15H8). The results contribute to our understanding of the predisposition of patients carrying FXII-Lys/Arg309 to angioedema after trauma, and reveal a regulatory function for the FXII HC that normally limits PK activation in plasma.

Original languageEnglish (US)
Pages (from-to)1152-1163
Number of pages12
JournalBlood
Volume133
Issue number10
DOIs
StatePublished - Mar 7 2019

Fingerprint

Hereditary Angioedemas
Factor XII
Prekallikrein
Kallikreins
Chemical activation
High Molecular Weight Kininogens
Thrombin
Peptide Hydrolases
Plasma (human)
Plasmas
Angioedema
Antithrombin III

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Ivanov, I., Matafonov, A., Sun, M. F., Mohammed, B. M., Cheng, Q., Dickeson, S. K., ... Gailani, D. (2019). A mechanism for hereditary angioedema with normal C1 inhibitor: an inhibitory regulatory role for the factor XII heavy chain. Blood, 133(10), 1152-1163. https://doi.org/10.1182/blood-2018-06-860270

A mechanism for hereditary angioedema with normal C1 inhibitor : an inhibitory regulatory role for the factor XII heavy chain. / Ivanov, Ivan; Matafonov, Anton; Sun, Mao Fu; Mohammed, Bassem M.; Cheng, Qiufang; Dickeson, S. Kent; Kundu, Suman; Verhamme, Ingrid M.; Gruber, Andras; McCrae, Keith; Gailani, David.

In: Blood, Vol. 133, No. 10, 07.03.2019, p. 1152-1163.

Research output: Contribution to journalArticle

Ivanov, I, Matafonov, A, Sun, MF, Mohammed, BM, Cheng, Q, Dickeson, SK, Kundu, S, Verhamme, IM, Gruber, A, McCrae, K & Gailani, D 2019, 'A mechanism for hereditary angioedema with normal C1 inhibitor: an inhibitory regulatory role for the factor XII heavy chain', Blood, vol. 133, no. 10, pp. 1152-1163. https://doi.org/10.1182/blood-2018-06-860270
Ivanov, Ivan ; Matafonov, Anton ; Sun, Mao Fu ; Mohammed, Bassem M. ; Cheng, Qiufang ; Dickeson, S. Kent ; Kundu, Suman ; Verhamme, Ingrid M. ; Gruber, Andras ; McCrae, Keith ; Gailani, David. / A mechanism for hereditary angioedema with normal C1 inhibitor : an inhibitory regulatory role for the factor XII heavy chain. In: Blood. 2019 ; Vol. 133, No. 10. pp. 1152-1163.
@article{ba1ca4eac0c54d8eb80ea82203c15b4d,
title = "A mechanism for hereditary angioedema with normal C1 inhibitor: an inhibitory regulatory role for the factor XII heavy chain",
abstract = "The plasma proteins factor XII (FXII) and prekallikrein (PK) undergo reciprocal activation to the proteases FXIIa and kallikrein by a process that is enhanced by surfaces (contact activation) and regulated by the serpin C1 inhibitor. Kallikrein cleaves high-molecular-weight kininogen (HK), releasing the vasoactive peptide bradykinin. Patients with hereditary angioedema (HAE) experience episodes of soft tissue swelling as a consequence of unregulated kallikrein activity or increased prekallikrein activation. Although most HAE cases are caused by reduced plasma C1-inhibitor activity, HAE has been linked to lysine/arginine substitutions for Thr309 in FXII (FXII-Lys/Arg309). Here, we show that FXII-Lys/Arg309 is susceptible to cleavage after residue 309 by coagulation proteases (thrombin and FXIa), resulting in generation of a truncated form of FXII (δFXII). The catalytic efficiency of δFXII activation by kallikrein is 15-fold greater than for full-length FXII. The enhanced rate of reciprocal activation of PK and δFXII in human plasma and in mice appears to overwhelm the normal inhibitory function of C1 inhibitor, leading to increased HK cleavage. In mice given human FXII-Lys/Arg309, induction of thrombin generation by infusion of tissue factor results in enhanced HK cleavage as a consequence of δFXII formation. The effects of δFXII in vitro and in vivo are reproduced when wild-type FXII is bound by an antibody to the FXII heavy chain (HC; 15H8). The results contribute to our understanding of the predisposition of patients carrying FXII-Lys/Arg309 to angioedema after trauma, and reveal a regulatory function for the FXII HC that normally limits PK activation in plasma.",
author = "Ivan Ivanov and Anton Matafonov and Sun, {Mao Fu} and Mohammed, {Bassem M.} and Qiufang Cheng and Dickeson, {S. Kent} and Suman Kundu and Verhamme, {Ingrid M.} and Andras Gruber and Keith McCrae and David Gailani",
year = "2019",
month = "3",
day = "7",
doi = "10.1182/blood-2018-06-860270",
language = "English (US)",
volume = "133",
pages = "1152--1163",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "10",

}

TY - JOUR

T1 - A mechanism for hereditary angioedema with normal C1 inhibitor

T2 - an inhibitory regulatory role for the factor XII heavy chain

AU - Ivanov, Ivan

AU - Matafonov, Anton

AU - Sun, Mao Fu

AU - Mohammed, Bassem M.

AU - Cheng, Qiufang

AU - Dickeson, S. Kent

AU - Kundu, Suman

AU - Verhamme, Ingrid M.

AU - Gruber, Andras

AU - McCrae, Keith

AU - Gailani, David

PY - 2019/3/7

Y1 - 2019/3/7

N2 - The plasma proteins factor XII (FXII) and prekallikrein (PK) undergo reciprocal activation to the proteases FXIIa and kallikrein by a process that is enhanced by surfaces (contact activation) and regulated by the serpin C1 inhibitor. Kallikrein cleaves high-molecular-weight kininogen (HK), releasing the vasoactive peptide bradykinin. Patients with hereditary angioedema (HAE) experience episodes of soft tissue swelling as a consequence of unregulated kallikrein activity or increased prekallikrein activation. Although most HAE cases are caused by reduced plasma C1-inhibitor activity, HAE has been linked to lysine/arginine substitutions for Thr309 in FXII (FXII-Lys/Arg309). Here, we show that FXII-Lys/Arg309 is susceptible to cleavage after residue 309 by coagulation proteases (thrombin and FXIa), resulting in generation of a truncated form of FXII (δFXII). The catalytic efficiency of δFXII activation by kallikrein is 15-fold greater than for full-length FXII. The enhanced rate of reciprocal activation of PK and δFXII in human plasma and in mice appears to overwhelm the normal inhibitory function of C1 inhibitor, leading to increased HK cleavage. In mice given human FXII-Lys/Arg309, induction of thrombin generation by infusion of tissue factor results in enhanced HK cleavage as a consequence of δFXII formation. The effects of δFXII in vitro and in vivo are reproduced when wild-type FXII is bound by an antibody to the FXII heavy chain (HC; 15H8). The results contribute to our understanding of the predisposition of patients carrying FXII-Lys/Arg309 to angioedema after trauma, and reveal a regulatory function for the FXII HC that normally limits PK activation in plasma.

AB - The plasma proteins factor XII (FXII) and prekallikrein (PK) undergo reciprocal activation to the proteases FXIIa and kallikrein by a process that is enhanced by surfaces (contact activation) and regulated by the serpin C1 inhibitor. Kallikrein cleaves high-molecular-weight kininogen (HK), releasing the vasoactive peptide bradykinin. Patients with hereditary angioedema (HAE) experience episodes of soft tissue swelling as a consequence of unregulated kallikrein activity or increased prekallikrein activation. Although most HAE cases are caused by reduced plasma C1-inhibitor activity, HAE has been linked to lysine/arginine substitutions for Thr309 in FXII (FXII-Lys/Arg309). Here, we show that FXII-Lys/Arg309 is susceptible to cleavage after residue 309 by coagulation proteases (thrombin and FXIa), resulting in generation of a truncated form of FXII (δFXII). The catalytic efficiency of δFXII activation by kallikrein is 15-fold greater than for full-length FXII. The enhanced rate of reciprocal activation of PK and δFXII in human plasma and in mice appears to overwhelm the normal inhibitory function of C1 inhibitor, leading to increased HK cleavage. In mice given human FXII-Lys/Arg309, induction of thrombin generation by infusion of tissue factor results in enhanced HK cleavage as a consequence of δFXII formation. The effects of δFXII in vitro and in vivo are reproduced when wild-type FXII is bound by an antibody to the FXII heavy chain (HC; 15H8). The results contribute to our understanding of the predisposition of patients carrying FXII-Lys/Arg309 to angioedema after trauma, and reveal a regulatory function for the FXII HC that normally limits PK activation in plasma.

UR - http://www.scopus.com/inward/record.url?scp=85062596730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062596730&partnerID=8YFLogxK

U2 - 10.1182/blood-2018-06-860270

DO - 10.1182/blood-2018-06-860270

M3 - Article

VL - 133

SP - 1152

EP - 1163

JO - Blood

JF - Blood

SN - 0006-4971

IS - 10

ER -